Theravance Biopharma TBPH Increase Decrease In Receivables For Milestone Payments

Other financials

Revenue$17.7M+15.0%

Operating income-$9.5M+34.3%

Net income-$4.9M+63.7%

EPS (diluted)-$0.10+63.0%

Cash & equivalents$288.1M+160%

Total debt$40.5M-15.9%

Total equity$290.6M+75.1%

Total assets$472.3M+37.5%

Operating cash flow$73.3M+70.3%

CapEx$8.0K-95.8%

Free cash flow$59.6M+5,560%

Market cap$896.51M+68.7%

Enterprise value$648.91M+38.3%

P/E7.8×—

P/S8.2×0.0×

Gross margin60.8%—

Operating margin1.2%+0.6pp

Net margin104.3%+71.4pp

FCF margin221.9%+206pp

Return on equity50.2%+36.2pp

Debt / equity0.1×-0.2×

Current ratio13.1×+8.4×

Reported directly by Theravance Biopharma in its filing.

Tagged under the XBRL concept tbph:IncreaseDecreaseInReceivablesForMilestonePayments.

The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is Theravance Biopharma's increase decrease in receivables for milestone payments?: Theravance Biopharma (TBPH) reported increase decrease in receivables for milestone payments of -$50M in Q1 2026.